Home > Insider Trading > Filing (0000899243-22-038098)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1750019	Tcr2 Therapeutics Inc.	TCRR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1556064	E Garry Menzel	C/O Tcr2 Therapeutics 100 Binney Street Cambridge MA 02142	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2022-12-07	9,111	$1.28	180,123	No	4	S	Direct
Common Stock	Disposition	2022-12-08	9,314	$1.25	170,809	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	132,729	Indirect	See Footnote
Common Stock	132,730	Indirect	See Footnote
Common Stock	189,234	Direct

Footnotes

Consists of 132,729 shares of common stock held by the Garry E. Menzel Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Menzel Trust"). The reporting person is the trustee of the Menzel Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Menzel Trust.
Consists of 132,730 shares of common stock held by and the Mary E. Henshall Revocable Trust of 2022, under Indenture of Trust dated April 5, 2022 (the "Henshall Trust"). The reporting person's spouse is the trustee of the Henshall Trust, and as such the reporting person may be deemed to beneficially own such securities. The reporting person and members of his immediate family are the sole beneficiaries of the Henshall Trust.
The sales reported represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.